PDCD1 and neoplasm: Using anti-PD-1/PD-L1 ICBs in conjunction with other cancer therapies will likely be more effective, since the therapy can act to kill the tumour cells, while the ICB can promote the activation of the host immune system so it can act with the therapy to eliminate the tumour.